Group B Streptococcus vaccine: state of the art

Area of Science:

• Microbiology
• Infectious Diseases
• Vaccinology

Background:

• Group B Streptococcus (GBS) is a major cause of invasive neonatal diseases, including sepsis and meningitis.
• GBS also poses a significant threat to the elderly and immunocompromised populations.
• Current prevention strategies for early-onset GBS disease are insufficient for late-onset disease and not universally applicable.

Purpose of the Study:

• To review the global burden of invasive GBS disease in infants and adults.
• To highlight current and emerging strategies for GBS vaccine development.
• To emphasize the need for novel GBS prevention and therapeutic approaches.

Main Methods:

• Literature review of studies on GBS epidemiology and disease burden.
• Analysis of current GBS prevention strategies, including screening and antibiotic prophylaxis.
• Overview of ongoing research and development in GBS vaccine candidates.

Main Results:

• Despite advances, GBS remains a significant global health concern, particularly for neonatal late-onset disease.
• Antibiotic prophylaxis during delivery has limited impact on late-onset GBS infections.
• Vaccine development is a promising strategy to control GBS infections.

Conclusions:

• An effective GBS vaccine is highly desirable for controlling invasive GBS disease in vulnerable populations.
• Continued research into GBS pathogenesis and vaccine platforms is essential.
• Vaccination offers a potential long-term solution to reduce the burden of GBS infections worldwide.